BusinessSummit Reports Positive Phase 1 New Formulation Data and Outlines Route to Market Strategy for DMD Candidate EzutromidBy Nasdaq OMXAug 9, 2016, 11:00 AM UTC
BusinessSummit Therapeutics to Present at 15th Annual Needham Healthcare ConferenceBy Nasdaq OMXApr 6, 2016, 11:00 AM UTC
BusinessSummit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients With DMDBy Nasdaq OMXMar 30, 2016, 11:00 AM UTC
BusinessSummit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMDBy Nasdaq OMXMar 15, 2016, 11:00 AM UTC
BusinessSummit Therapeutics Supports Ninth Annual Rare Disease DayBy Nasdaq OMXFeb 29, 2016, 12:35 PM UTC
